ALL YOU NEED TO KNOW ABOUT MODERNA RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE, mRNA-1345 

eAwazMedicine

LONDON – In January 2023, the US FDA granted mRNA-1345 Breakthrough Therapy Designation for the prevention of RSV-LRTD in adults aged 60 years or older, and mRNA-1345 was previously granted Fast Track designation by the U.S. FDA in August 2021.“We’ve seen the impact that respiratory viruses like RSV can have on the health and wellbeing of Canadians. As we approach …

MODERNA ASKS HEALTH CANADA TO REVIEW ITS RSV VACCINE, mRNA-1345

eAwazMedicine

mRNA-1345 is an investigational vaccine for the prevention of RSV in adults aged 60 years or older TORONTO – Moderna Biopharma Canada Corp. has announced the filing of a New Drug Submission (NDS) to Health Canada for mRNA-1345, its investigational vaccine candidate for the prevention of RSV in adults aged 60 years or older. This is the first mRNA vaccine …